December 06, 2024

Scientists Receives ERC Consolidator Grant – Funding for the Central Institute of Mental Health

Scientists Receives ERC Consolidator Grant – Funding for the Central Institute of Mental Health

An ERC Consolidator Grant will go to PD Dr Gordon Feld, who does research into sleep and memory at the Central Institute of Mental Health in Mannheim and teaches at Ruperto Carola’s Institute of Psychology.

PD Dr Gordon Feld | © Daniel Lukac/ZI

Dr Feld’s project, entitled “Tracking Memory During Sleep: Understanding How Replay of Complex Information Affects Memory and Mental Health” (MemoryTracker), is about how memories are processed during sleep and their potential capacity for treating mental disorders. His research focuses on discovering how current research findings can be transferred – inter alia with the aid of modern neuroscientific methods – into practical psychotherapeutic options. The European Research Council has allocated approximately two million euros to fund the studies over five years. Since 2019, Gordon Feld has headed the Emmy Noether Group “Psychology and Neurobiology of Sleep and Memory”, which is located in the Department Clinical Psychology at the Central Institute of Mental Health. The researcher also teaches at Heidelberg University’s Institute of Psychology.

The European Research Council awards the ERC Consolidator Grant to outstanding researchers with the aim of consolidating their academic independence. The central criterion for funding is scientific excellence.

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp